Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Julia Gracia-Gil"'
Autor:
Fernando Rodríguez-Jorge, José Ignacio Fernández-Velasco, Noelia Villarrubia, Julia Gracia-Gil, Eva Fernández, Virginia Meca-Lallana, Carolina Díaz-Pérez, Susana Sainz de la Maza, Eva María Pacheco, Ana Quiroga, Lluis Ramió-Torrentà, Sergio Martínez-Yélamos, Laura Bau, Enric Monreal, Ana López-Real, Alexander Rodero-Romero, Laura Borrega, Santiago Díaz, Pablo Eguía, Mercedes Espiño, Juan Luis Chico-García, Francisco Javier Barrero, María Luisa Martínez-Ginés, José Manuel García-Domínguez, Soraya De la Fuente, Irene Moreno, Raquel Sainz-Amo, M. Alba Mañé-Martínez, Ana Caminero, Fernando Castellanos, Ana Gómez López, Andrés Labiano-Fontcuberta, Lucía Ayuso, Rossana Abreu, Miguel Ángel Hernández, José Meca-Lallana, Lorena Martín-Aguilar, Alfonso Muriel García, Jaime Masjuan, Lucienne Costa-Frossard, Luisa María Villar
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with treatment r
Externí odkaz:
https://doaj.org/article/d000198e5e11421c9eafc7ac50f33ed2
Autor:
Eva Fernandez‐Diaz, Jose A. Perez‐Vicente, Ramon Villaverde‐Gonzalez, Leticia Berenguer‐Ruiz, Antonio Candeliere Merlicco, Maria Luisa Martinez‐Navarro, Julia Gracia Gil, Carlos M. Romero‐Sanchez, Arantxa Alfaro‐Saez, Inmaculada Diaz, Juana Gimenez‐Martinez, Maria Angeles Mendez‐Miralles, Jorge Millan‐Pascual, Javier Jimenez‐Pancho, Santiago Mola, Angel P. Sempere
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 2, Pp 385-394 (2021)
Abstract Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary saf
Externí odkaz:
https://doaj.org/article/36e53a30c73a4e0f8bca14d2d0533bc6
Autor:
Maria Angeles Mendez‐Miralles, Juana Gimenez-Martinez, Maria Luisa Martinez‐Navarro, Santiago Mola, Julia Gracia Gil, Inmaculada Diaz, Leticia Berenguer-Ruiz, Jose A. Perez‐Vicente, Javier Jimenez‐Pancho, Arantxa Alfaro‐Saez, Angel P. Sempere, Antonio Candeliere Merlicco, C.M. Romero-Sánchez, Eva Fernández-Díaz, Ramón Villaverde-González, Jorge Millan‐Pascual
Publikováno v:
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, Vol 8, Iss 2, Pp 385-394 (2021)
Annals of Clinical and Translational Neurology, Vol 8, Iss 2, Pp 385-394 (2021)
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe30c6d030ceab04f12648b0c62a65e
http://europepmc.org/articles/PMC7886031
http://europepmc.org/articles/PMC7886031
Autor:
Javier Sotoca, Maria A. Terzaghi, Julia Gracia-Gil, Jorge Maurino, Gustavo Saposnik, Luis Brieva, Ana B. Caminero, Carlos López de Silanes, Angel P. Sempere
Publikováno v:
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Background Risk attitude is defined as the willingness to tolerate risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and risk attitu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7765733180bc939fd12165c35d93672f
https://link.springer.com/article/10.1007/s40271-020-00454-3
https://link.springer.com/article/10.1007/s40271-020-00454-3
Autor:
Jorge, Maurino, Javier, Sotoca, Ángel P, Sempere, Luis, Brieva, Carlos, López de Silanes, Ana B, Caminero, María, Terzaghi, Julia, Gracia-Gil, Gustavo, Saposnik
Publikováno v:
The patient. 14(2)
Risk attitude is defined as the willingness to tolerate risk to achieve a greater expected return. Limited information is available on how relapsing-remitting multiple sclerosis people's perceptions about disease trajectory and risk attitude may infl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e9b8ba261c733f8b9d3410076e28b183
https://pubmed.ncbi.nlm.nih.gov/32975737
https://pubmed.ncbi.nlm.nih.gov/32975737
Autor:
Carlos Manuel Romero-Sánchez, Inmaculada Díaz-Maroto, Eva Fernández-Díaz, Álvaro Sánchez-Larsen, Almudena Layos-Romero, Jorge García-García, Esther González, Inmaculada Redondo-Peñas, Ana Belén Perona-Moratalla, José Antonio Del Valle-Pérez, Julia Gracia-Gil, Laura Rojas-Bartolomé, Inmaculada Feria-Vilar, María Monteagudo, María Palao, Elena Palazón-García, Cristian Alcahut-Rodríguez, David Sopelana-Garay, Yóscar Moreno, Javaad Ahmad, Tomás Segura
Publikováno v:
SSRN Electronic Journal.
Background: The coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019 Spain is one of the most affected countries, with high incidence a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e600ebfeac0bbd3344b3bbed4882184e
https://doi.org/10.2139/ssrn.3594578
https://doi.org/10.2139/ssrn.3594578
Autor:
José Marín Marín, Ramón Villaverde-González, María Carcelén Gadea, Julia Gracia Gil, Laura Gabaldón Torres, Antonio Candeliere Merlicco, Angel P. Sempere, Antonio Moreno Escribano, Jorge Millán Pascual
Publikováno v:
EUROPEAN NEUROLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
EUR NEUROL
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
EUR NEUROL
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Objective: To determine the effect of disease-modifying drugs (DMDs) on disease activity rebound in patients discontinuing natalizumab (NTZ). Methods: Twenty-one patients with relapsing-remitting multiple sclerosis (RRMS) treated with NTZ for ≥1 ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28ecebaf163bea6d0745e5d1e7dd788
https://pubmed.ncbi.nlm.nih.gov/28052269
https://pubmed.ncbi.nlm.nih.gov/28052269